Development of new cancer chemoprevention agents: Role of pharmacokinetic/pharmacodynamic and intermediate endpoint biomarker monitoring

Clinical Chemistry

Volumn 44, Issue 2, 1998, Pages 420-427

  Lieberman, Ronald ^a   Crowell, James A ^a   Hawk, Ernest T ^a   Boone, Charles W ^a   Sigman, Caroline C ^a   Kelloff, Gary J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; ANTIESTROGEN; ANTINEOPLASTIC AGENT; CYCLOOXYGENASE 2 INHIBITOR; EFLORNITHINE; FENRETINIDE; FLURBIPROFEN; FLUTAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OLTIPRAZ; PIROXICAM; RETINOIC ACID RECEPTOR; RETINOID; SOMATOMEDIN C; SULINDAC; TAMOXIFEN; TUMOR MARKER;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PREVENTION; CLINICAL TRIAL; COLON CANCER; CONFERENCE PAPER; DOSE RESPONSE; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG MONITORING; HUMAN; PHARMACODYNAMICS; PROSTATE CANCER;

EID: 0031911672     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/44.2.420     Document Type: Conference Paper

References (20)

1. Lieberman R, Nelson R. Dose-response and concentration-response relationships: clinical and regulatory perspectives. Ther Drug Monit 1995;15:498-502.
2. Kelloff GJ, Boone CW, Crowell JA, Steele VE, Lubet R, Doody LA. Surrogate endpoint biomarkers for phase 2 cancer chemoprevention trials. J Cell Biochem 1994;19:1-9.
3. Boolbol SK, Dannenberg AJ, Chadburn A, Martucci C, Guo XJ, Ramonetti JT, et al. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res 1996;56:2556-60.
4. McCracken JD, Jacoby RF, Kantoci D, Murray ED, Wechter W. The effect of R-flurbiprofen on inhibition of polyp formation in the Min mouse model [Abstract]. Gastroenterology 1996;110:A555.
5. Formelli F, Clerici M, Campa T, Di Mauro MG, Magni A, Mascotti G, et al. Five-year administration of fenretinide:pharmacokinetics and effects on plasma retinol concentrations. J Clin Oncol 1993; 11:2036-42.
6. Rotmenze N, DePalo G, Formelli F, Costa A, Marubini E, Campa E, et al. Long-term tolerability of fenretinide (4-HPR) in breast cancer patients. Eur J Cancer 1991;27:1127-31.
7. Kelloff G, Hawk E, Crowell JA, Boone CW, Nayfield S, Perloff M, et al. Strategies for identification and clinical evaluation of promising chemopreventive agents. Oncology 1996;10:1471-80.
8. Kelloff GJ, Hawk ET, Karp JE, Crowell JA, Boone CW, Steele VE, et al. Progress in clinical chemoprevention. Semin Oncol 1997;24: 241-52.
9. Smith MK, Goral M, Wright JH, Matrisian LM, Morris RJ, Klein-Szanto AJP, et al. Ornithine decarboxylase overexpression leads to increased epithelial tumor invasiveness. Cancer Res 1997;57: 2104-8.
10. Macaulay VL. Insulin-like growth factors and cancer. Br J Cancer 1992;65:311-20.
11. Torrisi R, Pensa F, Orengo MA, Catsafados E, Ponzani P, Boccardo F, et al. The synthetic retinoid fenretinide lowers plasma insulin-like growth factor 1 levels in breast cancer patients. Cancer Res 1993;53:4769-71.
12. Khuri FR, Lippman SM, Spitz MR, Lotan R, Hong WK. Molecular epidemiology and retinoid chemoprevention of head and neck cancer. J Natl Cancer Inst 1997;89:199-211.
13. Lotan R, Xu XC, Lippman SM, Ro JY, Lee JS, Lee JJ, et al. Suppression of retinoic acid receptor-beta in premalignant oral lesions and its upregulation by isotretinoin. N Engl J Med 1995; 332:1405-10.
14. Kelloff GJ, Johnson JR, Crowell JA, Boone CW, DeGeorge J, Steele VE, et al. Approaches to the development and marketing approval of drugs that prevent cancer. Cancer Epidemiol Biomarkers Prev 1995;4:1-10.
15. Prentice R. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989;8:431-40.
16. Cronin KA, Lieberman R, Freedman LS, Weiss HL, Beenken SW, Kelloff GJ. Bayesian sequential analysis of intermediate end points in cancer prevention trials [Abstract]. Proc Am Assoc Cancer Res 1998;A2065.
17. News, Comment. A catalog of cancer genes at the click of a mouse. Science 1997;276:1023-4.
18. Emmert-Buck M, Bonner RF, Smith PD, Chuaqui RF, Zhuang Z, Goldstein SR, et al. Laser capture microdissection. Science 1996;274:998-1001.
19. Hacia JG, Brody LC, Chee MS, Fodor SP, Collins F. Detection of heterozygous mutations in BRCA1 using high density oligonucleotide arrays and two-colour fluorescence analysis. Nature Genet 1996;14:441-7.
20. DeRisi J, Penland L, Brown PO, Bitner ML, Meltzer PS, Ray M, et al. Use of a cDNA microarray to analyze gene expression patterns in human cancer. Nature Genet 1996;14:457-60.